Medifast (NYSE: MED) director receives 11,680 restricted stock units award

Rhea-AI Filing Summary

SCHLACKMAN SCOTT reported acquisition or exercise transactions in this Form 4 filing.

Medifast Inc. director Scott Schlackman received an award of 11,680 restricted stock units as part of his annual director fees. Each unit represents one share of common stock granted under the company’s share incentive plan and is scheduled to vest in full on May 26, 2027. Following this grant, Schlackman directly holds 42,228.707 shares of common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider SCHLACKMAN SCOTT

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	11,680	$0.00	--

Holdings After Transaction: Common Stock — 42,228.707 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSUs granted: 11,680 units Grant price: $0.00 per share Post-transaction holdings: 42,228.707 shares +1 more

4 metrics

RSUs granted 11,680 units Restricted stock units granted to director as fees

Grant price $0.00 per share Reported transaction price per share for the award

Post-transaction holdings 42,228.707 shares Common stock directly held after the grant

Vesting date May 26, 2027 RSUs vest in full on this date

Key Terms

restricted stock units, Director's Deferred Compensation Plan, Amended and Restated 2012 Share Incentive Plan, annual director fees

4 terms

restricted stock units financial

"These restricted stock units were granted under the Medifast, Inc. Director's Deferred Compensation Plan"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Director's Deferred Compensation Plan financial

"granted under the Medifast, Inc. Director's Deferred Compensation Plan, as Amended and Restated"

Amended and Restated 2012 Share Incentive Plan financial

"These shares are granted from the Issuer's Amended and Restated 2012 Share Incentive Plan"

annual director fees financial

"in connection with the payment of the reporting person's annual director fees"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SCHLACKMAN SCOTT

(Last) (First) (Middle)

C/O MEDIFAST, INC.

1501 S. CLINTON STREET, SUITE 500

(Street)

BALTIMORE MARYLAND 21224

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MEDIFAST INC [ MED ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/26/2026		A		11,680(1)	A	$0	42,228.707	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These restricted stock units were granted under the Medifast, Inc. Director's Deferred Compensation Plan, as Amended and Restated (the "Plan"), in connection with the payment of the reporting person's annual director fees. Each unit represents the right to receive one share of the Issuer's common stock. These shares are granted from the Issuer's Amended and Restated 2012 Share Incentive Plan and will vest in full on May 26, 2027.

Remarks:

	/s/ James P. Maloney, attorney-in-fact	05/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Medifast (MED) report for Scott Schlackman?

Medifast reported that director Scott Schlackman received 11,680 restricted stock units as part of his annual director fees. Each unit represents one share of common stock, granted at no cash cost to him.

What are the terms of the 11,680 restricted stock units granted at Medifast (MED)?

The 11,680 restricted stock units represent rights to receive an equal number of Medifast common shares. They were granted under director compensation and will vest in full on May 26, 2027, if the vesting conditions are met.

How many Medifast (MED) shares does Scott Schlackman hold after this grant?

After the grant, Scott Schlackman is reported to directly hold 42,228.707 shares of Medifast common stock. This total includes the impact of the newly awarded restricted stock units reflected in the Form 4 filing.

Was the Medifast (MED) grant to Scott Schlackman a market purchase or sale?

The transaction was a grant or award of 11,680 restricted stock units, not an open-market purchase or sale. The units were issued as compensation for his role as a director, with a reported price of $0.00 per share.

When will Scott Schlackman’s Medifast (MED) restricted stock units vest?

The restricted stock units granted to Scott Schlackman are scheduled to vest in full on May 26, 2027. Vesting means each unit will convert into one share of Medifast common stock, assuming the vesting terms are satisfied.